tiprankstipranks
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

Cantargia Secures SEK 50 Million Financing to Extend Financial Runway
Company AnnouncementsCantargia Secures SEK 50 Million Financing to Extend Financial Runway
3d ago
Cantargia’s Nadunolimab Receives FDA Fast Track Designation
PremiumCompany Announcements
Cantargia’s Nadunolimab Receives FDA Fast Track Designation
10d ago
Cantargia’s CAN10 Antibody Shows Promise in Inhibiting Vascular Inflammation
PremiumCompany Announcements
Cantargia’s CAN10 Antibody Shows Promise in Inhibiting Vascular Inflammation
1M ago
Cantargia AB Announces Key Resolutions from Annual General Meeting
PremiumCompany Announcements
Cantargia AB Announces Key Resolutions from Annual General Meeting
1M ago
Cantargia AB’s Promising Interim Report for Early 2025
PremiumCompany Announcements
Cantargia AB’s Promising Interim Report for Early 2025
1M ago
Cantargia’s CAN10 Achieves Promising Phase 1 Results, Sets Stage for Phase 2
PremiumCompany AnnouncementsCantargia’s CAN10 Achieves Promising Phase 1 Results, Sets Stage for Phase 2
1M ago
Cantargia’s Nadunolimab Shows Promise in Solid Tumor Treatment
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Solid Tumor Treatment
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
PremiumCompany AnnouncementsCantargia’s Nadunolimab Shows Promise in Overcoming Cancer Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Induced Immune Suppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Tumor-Induced Immune Suppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Overcoming Tumor-Induced Immune Suppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Driven Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Driven Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Driven Immunosuppression
PremiumCompany Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor-Driven Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Tumor Immunosuppression
PremiumCompany AnnouncementsCantargia’s Nadunolimab Shows Promise in Overcoming Tumor Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Counteracting Tumor Immunosuppression
2M ago
Cantargia’s Nadunolimab Shows Promise in Overcoming Tumor Immunosuppression
Premium
Company Announcements
Cantargia’s Nadunolimab Shows Promise in Overcoming Tumor Immunosuppression
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >